Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5791081 | 0.90 | ALDH1A1 (0.45) | TLR4ALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL4077853 | 0.88 | TLR4 (0.55) | TLR4ALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL5659584 | 0.81 | TLR4 (0.50) | TLR4ALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL11782843 | 0.81 | CYP1A2 (0.38) | TLR4ALDH1A1HSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL14877461 | 0.81 | GAA (0.37) | TLR4ALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL8187713 | 0.80 | TLR4 (0.49) | TLR4ALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL4080364 | 0.80 | ALDH1A1 (0.51) | TLR4ALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL25014921 | 0.79 | TLR4 (0.48) | TLR4ALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL5896856 | 0.78 | TLR4 (0.47) | TLR4ALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL3362070 | 0.77 | CYP1A2 (0.38) | ALDH1A1HSD17B10KDM4ESMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729510-A1 | INDOLE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Merna Therapeutics Co. Ltd (CN) | 2026-04-22 | — | — | EP | disclosed |
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250290137-A1 | SUBSTITUTED COUMARIN DYES AND USES AS FLUORESCENT LABELS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2025-09-18 | — | — | US | disclosed |
| US-12351871-B2 | Substituted coumarin dyes and uses as fluorescent labels | ILLUMINA CAMBRIDGE LIMITED (GB) | 2025-07-08 | — | — | US | disclosed |
| WO-2025124365-A1 | CRYSTAL FORM OF RNA M6A REGULATOR, PREPARATION METHOD FOR CRYSTAL FORM AND USE THEREOF | 苏州湃芮生物科技有限公司 | 2025-06-19 | — | — | WO | disclosed |
| CN-120136769-A | Crystalline form of RNA m6A modulator, and preparation method and application thereof | 苏州湃芮生物科技有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120118019-A | Eutectic form of RNA m6A modulator and preparation method and application thereof | 苏州湃芮生物科技有限公司 | 2025-06-10 | — | — | CN | disclosed |
| WO-2025007928-A1 | INDOLE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州湃芮生物科技有限公司 | 2025-01-09 | — | — | WO | disclosed |
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240271209-A1 | SUBSTITUTED COUMARIN DYES AND USES AS FLUORESCENT LABELS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-08-15 | — | — | US | disclosed |
| US-4423056-A | 5(Aminomethyl)-4,5,6,7-tetrahydro[d]thiazole containing compositions for and medical use in treating circulatory insufficiencies | LABORATOIRES JACQUES LOGEAIS (FR) | 1983-12-27 | — | — | US | disclosed |
| US-4337343-A | INCREASES CIRCULATION | LABORATOIRES JACQUES LOGEAIS (FR) | 1982-06-29 | — | — | US | disclosed |
| US-4107165-A | ANTICOAGULANTS | ENDO LABORATORIES (US) | 1978-08-15 | — | — | US | disclosed |
| US-4057640-A | ANTIINFLAMMATORY | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-11-08 | — | — | US | disclosed |
| US-3988444-A | Novel thiazole derivatives as insecticides and acaricides | ROUSSEL-UCLAF (FR) | 1976-10-26 | — | — | US | disclosed |
| US-3979391-A | 1,2,3,4-Tetrahydrocarbazoles | STERLING DRUG INC. (US) | 1976-09-07 | — | — | US | disclosed |
| US-3956295-A | ANTIINFLAMMATORY | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-05-11 | — | — | US | disclosed |
| US-3948939-A | 9-Acyl-1,2,3,4-tetrahydrocarbazole-3 and 4-carboxylic acids | STERLING DRUG INC. (US) | 1976-04-06 | — | — | US | disclosed |
| US-3939177-A | 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles | STERLING DRUG INC. (US) | 1976-02-17 | — | — | US | disclosed |
| US-3932433-A | ACRACIDES | ROUSSEL-UCLAF (FR) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | TLR4 3995/4885ALDH1A1 919/4885KMT2A 2379/4885 |
| US-20250290137-A1 | SUBSTITUTED COUMARIN DYES AND USES AS FLUORESCENT LABELS | FBL, DUT, PHAX | TLR4 2021/4885ALDH1A1 475/4885KMT2A 3586/4885 |
| US-20240271209-A1 | SUBSTITUTED COUMARIN DYES AND USES AS FLUORESCENT LABELS | FBL, DUT, PHAX | TLR4 2021/4885ALDH1A1 475/4885KMT2A 3586/4885 |
| US-12351871-B2 | Substituted coumarin dyes and uses as fluorescent labels | FBL, DUT, PHAX | TLR4 2021/4885ALDH1A1 475/4885KMT2A 3586/4885 |
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SLC6A3, SLC6A11, SLC6A13 | TLR4 938/4885ALDH1A1 1362/4885KMT2A 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.